ClinicalTrials.gg
WithdrawnNCT04604678Updated Oct 4, 2022

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

A Phase 2 interventional study of Metformin and Naltrexone in Covid19, sponsored by AgelessRx. Withdrawn at 1 site in United States. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by AgelessRx · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Unable to recruit participants due to restrictive inclusion/exclusion criteria. Will update protocol with IRB \& begin anew after approval.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
1,240th of 1,321
0 · median 91
Started
2021
with 503 others
Phase 2
349 of 1,859
14 open now
Registered
767th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 1,240th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 349 in phase 2, and was the 767th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.

Read the detailed description

The researchers will treat 40 patients with metformin (1500 mg/day) and LDN (4.5 mg/day) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19. These 40 patients will be compared with 40 control patients who will receive regular care. All patients will be asked to complete surveys at baseline and after 1, 2, and 4 weeks after initiation of treatment. The difference with baseline at each time point will be assessed. The surveys will assess COVID-19 symptoms severity.

03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • metformin
  • LDN
  • low dose naltrexone
  • COVID-19
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 30-70
  • Any sex
  • Any ethnicity
  • Adequate cognitive function to be able to give
  • Technologically competent to complete web forms and perform video calls with the PI
  • Positive PCR (polymerase chain reaction) test result for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) within the last 10 days
  • At least two COVID-19 symptoms as assessed by laboratory or patient self-reporting started within the last 3 days
  • Willing to fill out regular questionnaires
  • Willing to take metformin and LDN

Exclusion criteria

Exclusion Criteria:

  • hepatic, renal, or cardiac impairment (as determined by previous clinical judgement)
  • Hypoglycemia
  • Currently on drugs for COVID-19
  • Hospitalization for COVID-19
  • (Suspected) pregnancy or breastfeeding
  • Active cancer
  • Uncontrolled mental health issues
  • On any medication with major interactions with metformin or LDN
  • Taking opioid analgesics, or being treated for opioid addiction/recovery
  • Opioid dependence or withdrawal syndrome
  • Known sensitivity to metformin or naltrexone
  • Current users of metformin or naltrexone
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment with Metformin and LDN

    Patients will be treated with 1500 mg/day of metformin and 4.5 mg/day of LDN for a total of 4 weeks.

    Drug: Metformin · Drug: Naltrexone

  • No intervention
    Regular health care comparison group

    Patients will receive regular health care and will serve as a control group.

Interventions

  • Metformin at 1500 mg/day

  • Naltrexone at 4.5 mg/day (LDN)

    Also known as: LDN

06

What researchers measure

Primary outcomes

  1. Reduction of COVID-19 symptoms after 1 week of treatment with metformin and LDN

    Reduction in COVID-19 symptoms as measured with the COVID-19 Symptoms Severity Scale. The scale has a minimum score of 0 and a maximum of 24, with values ranging from 4-11 are considered 'mild symptoms', scores ranging 12-19 are considered 'moderate', and scores 20-24 are considered 'severe'.

    Time frame: 1 week

  2. Reduction of COVID-19 symptoms after 2 weeks of treatment with metformin and LDN

    Reduction in COVID-19 symptoms as measured with the COVID-19 Symptoms Severity Scale. The scale has a minimum score of 0 and a maximum of 24, with values ranging from 4-11 are considered 'mild symptoms', scores ranging 12-19 are considered 'moderate', and scores 20-24 are considered 'severe'.

    Time frame: 2 weeks

Secondary outcomes

  1. Reduction in recovery time from COVID-19

    Reduction in the number of days with symptoms due to COVID-19 upon treatment with metformin and LDN, compared to placebo group

    Time frame: 4 weeks

  2. Reduction in hospitalizations

    Reduction in the number of patients being hospitalized due to COVID-19 upon treatment with metformin and LDN, compared to placebo group

    Time frame: 4 weeks

  3. Reduction in requirement of additional treatment due to COVID-19

    Reduction in the number of patients requiring additional treatment for COVID-19 upon treatment with metformin and LDN, compared to placebo group

    Time frame: 4 weeks

  4. Reduction in mortality

    Reduction in the number of mortality cases due to COVID-19 upon treatment with metformin and LDN, compared to placebo group

    Time frame: 4 weeks

07

Study locations

1 site
  • AgelessRx
    Ann Arbor, Michigan 48104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2021; primary completion for Aug 2021, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Oct 27, 2020
StartEst.
Feb 2021
Primary completionEst.
Aug 2021
CompletionEst.
Oct 2021
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04604678
Lead sponsor
AgelessRx
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Feb 2021 (estimated)
Primary completion
Aug 2021 (estimated)
Completion
Oct 2021 (estimated)
Last update
Oct 4, 2022

Study contacts

Sajad Zalzala, MD
study director · AgelessRx
Sajad Zalzala, MD
principal investigator · AgelessRx

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Naltrexone

Start the discussion